Pharmafile Logo
Pharmafocus logo
Advanced Search
sunpharma

Sun Pharma agree deal to distribute AstraZeneca type-2 diabetes drug in India

March 24, 2016
Sales and Marketing AstraZeneca, India, Sun Pharma, diabetes, oxra, type 2, type-2

Sun Pharma has agreed a deal with AstraZeneca to promote and distribute their type-2 diabetes drug, dapagliflozin, in India. Marketed …

News
msd

MSD teams up with Harvard to develop new leukaemia treatments

March 24, 2016
Medical Communications, Research and Development AML, Harvard, MSD, leukaemia

MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …

News

EMA to review Pfizer’s Xeljanz for patients with rheumatoid arthritis

March 24, 2016
Research and Development, Sales and Marketing EMA, Pfizer, Xeljanz, approval, authorisation, marketing, review, rheumatoid arthritis

Pfizer (NYSE: PFE) has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) …

News
novartis_pic

Novartis settles bribery charges in China for $25m

March 24, 2016
Medical Communications, Sales and Marketing Novartis

Novartis will pay $25 million to the US Government’s Securities and Exchange Commission to settle charges that it bribed healthcare …

News
teva_copy

Teva announces FDA approval for asthma injection, Cinqair

March 24, 2016
Research and Development, Sales and Marketing FDA, Teva, approval, asthma, cinqair

The US Food and Drug Administration has approved Cinqair (reslizumab), an injection for patients with severe asthma developed by Teva …

News

Biotech Micreos appoints CMO to lead clinical development of antibiotic alternative

March 23, 2016
Research and Development

Dr Johan Frieling has been appointed as the new chief medical officer of Dutch biotech company Micreos, at a pivotal …

Appointment
sanofi_pasteur_scientist

Sanofi and Regeneron meet endpoint in Phase III Praluent study

March 23, 2016
Research and Development Regeneron, Sanofi, endpoint, escape, hefh, odyssey, phase 3, phase III, positive, praulent, trial

Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …

News
bms_good

Bristol-Myers Squibb to acquire Padlock Therapeutics for up to $600m

March 23, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Padlock Therapeutics, rheumatoid arthritis

Bristol-Myers Squibb is to acquire Massachusetts-based auto-immune disease specialist Padlock Therapeutics in a deal worth up to $600 million. The …

News
china-pharmaceutical-industry

Thirty-seven arrested in China vaccine scandal

March 23, 2016
Sales and Marketing China, vaccines

Police in China have arrested 37 people in eastern China in relation to illegal vaccine sales conducted by a ring …

News
brilinta

AstraZeneca’s Brilinta fails to best aspirin in treating stroke patients

March 23, 2016
Research and Development AstraZeneca, Brilinta, stroke

AstraZeneca has announced top-line results from the Phase III SOCRATES trial, confirming that twice-daily doses of its drug Brilinta (ticagrelor) failed …

News

PCI Pharma Services’ Hay-on-Wye site launches specialist packaging design department

March 23, 2016
Manufacturing and Production

Leading pharmaceutical outsourcing provider PCI Pharma Services has launched Technical Services, a new packaging design and development function, at its …

News
Press release
sovaldi-web

Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute

March 23, 2016
Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi

Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …

News

NDA Group and PharmApprove announce merger

March 23, 2016
Sales and Marketing NDA Group

NDA Group, a leading strategic regulatory and HTA consultancy in Europe, and PharmApprove, a leading strategic regulatory and scientific communications …

News
Press release
eli_lilly

FDA approves Lilly’s plaque psoriasis drug Taltz

March 23, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …

News
fda_sign_web

FDA announces strongest warnings for opioid pain medications

March 23, 2016
Medical Communications, Research and Development FDA, abuse, addiction, boxed, label, misuse, opioids, public health, restrictions, safety, warnings

The US Food and Drug Administration has announced class-wide safety labelling changes for immediate release (IR) opioid pain medications. The …

News
nice

NICE draft guidance says ‘no’ to cystic fibrosis drug Orkambi

March 23, 2016
Research and Development, Sales and Marketing NICE, Orkambi, Vertex, cystic fibrosis

NICE has issued draft guidance not recommending Vertex’s Orkambi (lumacaftor/ivacaftor) for use on the National Health Service (NHS) in England …

News
jose_conejo-garcia_-_wistar_institute

Targeted cancer therapies can suppress T cell immune responses, study finds

March 23, 2016
Research and Development T cell, anti-cancer drugs, immunosuppresive, superagonist, wistar institute

Researchers at the Wistar Institute have developed a new method whereby targeted cancer therapies can provide appropriate therapeutics without supressing …

News
shutterstock_141299494

Celyad teams-up with Institut Curie to advance its immuno-oncology program

March 22, 2016
Manufacturing and Production, Research and Development Cancer Immunotherapy, Celyad, Institut Curie, cellular immunotherapies

Celyad (Nasdaq: CYAD) on Tuesday said it has partnered with Institut Curie to develop its NKR-T pipeline in cellular immunotherapies …

News
2174264_eisai_logo

Eisai withdraws application for neurodegenerative-disease drug in Japan

March 22, 2016
Manufacturing and Production, Research and Development Eisai, mecobalamin, neurodegenerative disease

Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat …

News

BioMarin reports mixed Phase III results for genetic disorder trial-drug Pegvaliase

March 22, 2016
Manufacturing and Production, Research and Development

Biotech firm BioMarin Pharmaceutical (Nasdaq: BMRN) reported mixed results for its trial drug to treat genetic disorder phenylketonuria. Trial drug, …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026